Fi3 FINANCIAL ADVISORS LLC Purchases Shares of 2,386 Gilead Sciences, Inc. (NASDAQ:GILD)

Fi3 FINANCIAL ADVISORS LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,386 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Several other hedge funds have also added to or reduced their stakes in the business. Southland Equity Partners LLC lifted its holdings in Gilead Sciences by 3.6% during the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares during the last quarter. Berkshire Bank lifted its holdings in Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 111 shares during the last quarter. CFO4Life Group LLC lifted its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 112 shares in the last quarter. GHP Investment Advisors Inc. lifted its holdings in shares of Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 122 shares in the last quarter. Finally, J.W. Cole Advisors Inc. lifted its holdings in shares of Gilead Sciences by 1.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 13,597 shares of the biopharmaceutical company’s stock worth $1,256,000 after buying an additional 135 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $107.08 on Friday. The business’s 50-day moving average price is $103.68 and its 200-day moving average price is $93.75. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market capitalization of $133.35 billion, a price-to-earnings ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.52.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 over the last ninety days. 0.29% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.